Skip to main content

Market Overview

Don't Brush Off An Opportunity To Buy Colgate-Palmolive Right Now

Share:
Don't Brush Off An Opportunity To Buy Colgate-Palmolive Right Now

Morgan Stanley said in a note, with Colgate-Palmolive Company (NYSE: CL), it sees a rare opportunity to buy a well-positioned business at valuation level close to structurally less attractive peers. The firm noted that the stock of the company has underperformed due to its transitory top-line slowdown compared to peers.

As such, the firm upgraded shares of Colgate-Palmolive to Outperform and bumped up its price target from $75 to $84.

At the time of writing, shares of Colgate-Palmolive were surging up 3.54 percent to $73.71.

Analyst Dara Mohsenian termed Colgate-Palmolive as Morgan Stanley's top household products pick. At the same time, the analyst noted in the firm's recent investor survey, the company scored the lowest on sentiment among its mega-cap staples names.

The analyst clarified that the pessimism toward the company stemmed from the company disappointing on its organic sales growth for three straight quarters and sub-par earnings per share quality after years of moderating ad spend.

See also: Benzinga's Top Upgrades, Downgrades For September 25, 2017

Morgan Stanley thinks the market views the company as an average mega-cap, with valuation close to peer levels after nearly 600 bps of relative multiple compression since the end of May.

However, the firm's analytical work pointed toward a significant top-line growth inflection, beginning in the fourth quarter. The firm believes top-line upside and favorable forex would help to drive earnings per share upside relative to the consensus, catalyzing multiple expansion.

"Our new $84 PT is based on ~24.5x times our upwardly revised FY19 EPS estimate (~23xex a 7.5% strategic halo), representing a ~20% return with a ~2% dividend yield," the firm said.

"Furthermore, we see a 2:1 ratio of bull case upside relative to bear case downside."

Related Link: If Colgate's Looking To Sell Itself, Would Berkshire Be Looking To Buy?

Latest Ratings for CL

DateFirmActionFromTo
Feb 2021Credit SuisseUpgradesUnderperformNeutral
Jan 2021StifelDowngradesBuyHold
Jan 2021BerenbergUpgradesSellHold

View More Analyst Ratings for CL
View the Latest Analyst Ratings

 

Related Articles (CL)

View Comments and Join the Discussion!

Posted-In: Analyst Color Long Ideas News Upgrades Price Target Analyst Ratings Movers Trading Ideas Best of Benzinga

Latest Ratings

StockFirmActionPT
KRYSHC Wainwright & Co.Maintains103.0
OTRKRBC CapitalDowngrades32.0
EVHCanaccord GenuityMaintains24.0
BMRNCanaccord GenuityMaintains91.0
ONTFCanaccord GenuityInitiates Coverage On65.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com